Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06445062
PHASE1/PHASE2

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Sponsor: Revolution Medicines, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel

Official title: A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1130

Start Date

2024-05-24

Completion Date

2027-07-15

Last Updated

2026-04-01

Healthy Volunteers

No

Interventions

DRUG

RMC-6236

Oral tablet

DRUG

mFOLFOX6 regimen

IV infusion

DRUG

bevacizumab

IV infusion

DRUG

mFOLFIRINOX regimen

IV infusion

DRUG

cetuximab

IV infusion

DRUG

gemcitabine

IV infusion

DRUG

nab-paclitaxel

IV infusion

DRUG

RMC-9805

Oral Tablet

Locations (32)

Ironwood Cancer and Research Centers

Chandler, Arizona, United States

Mayo Clinic Hospital

Phoenix, Arizona, United States

HonorHealth Research Institute

Scottsdale, Arizona, United States

UC San Diego Moores Cancer Center

La Jolla, California, United States

Cedars-Sinai Cancer at Cedars-Sinai Medical Center

Los Angeles, California, United States

UCLA Hematology/Oncology- Santa Monica

Los Angeles, California, United States

University of Colorado Hospital-Anschutz Cancer Pavilion

Aurora, Colorado, United States

Yale-New Haven Hospital-Yale Cancer Center

New Haven, Connecticut, United States

Mayo Clinic Cancer Center

Jacksonville, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

The University of Kansas Clinical Research Center

Westwood, Kansas, United States

The Sidney Kimmel Comprehensive Cancer Center at John Hopkins

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Nebraska Cancer Specialists

Omaha, Nebraska, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Atlantic Health System

Morristown, New Jersey, United States

Northwell Health / RJ Zuckerberg Cancer Center

Lake Success, New York, United States

Columbia University Medical Center

New York, New York, United States

Memorial Sloan Kettering Cancer Center Main Campus

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

Baylor College of Medicine

Houston, Texas, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

NEXT Oncology Dallas

Irving, Texas, United States

Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States